Microvascular Dysfunction as a Systemic Disease: A Review of the Evidence - 26/08/22

Abstract |
Microvascular dysfunction describes a varied set of conditions that includes vessel destruction, abnormal vasoreactivity, in situ thrombosis, and fibrosis, which ultimately results in tissue damage and progressive organ failure. Microvascular dysfunction has a wide array of clinical presentations, ranging from ischemic heart disease to renal failure, stroke, blindness, pulmonary arterial hypertension, and dementia. An intriguing unifying hypothesis suggests that microvascular dysfunction of specific organs is an expression of a systemic illness that worsens with age and is accelerated by vascular risk factors. Studying relationships across a spectrum of microvascular diseases affecting the brain, retina, kidney, lung, and heart may uncover shared pathologic mechanisms that could inform novel treatment strategies. We review the evidence that supports the notion that microvascular dysfunction represents a global pathologic process. Our focus is on studies reporting concomitant microvascular dysfunction of the heart with that of the brain, kidney, retina, and lung.
Le texte complet de cet article est disponible en PDF.Keywords : Coronary microvascular dysfunction, Microvascular dysfunction, Small vessel disease
Plan
| Funding: This work was supported by Department of Defense-funded WARRIOR trial [W81XWH-17-2-0030] (CJP), the McJunkin Family Foundation for the WARRIOR Biorepository (CJP), the American Heart Association [18TPA34170486] (BM), and by contracts from the National Heart, Lung and Blood Institutes nos. R01 HL153500 (Wei), R01 AI135128 (BM), and N01-HV-68161, N01-HV-68162, N01-HV-68163, N01-HV-68164, grants U0164829, U01 HL649141, U01 HL649241, K23 HL125941, T32 HL69751, R01 HL090957, 1R03 AG032631, R01 HL146158, R01 HL124649, PR150224P1 (CDMRP-DoD), U54 AG065141, GCRC grant M01-RR00425 from the National Center for Research Resources, the National Center for Advancing Translational Sciences Grant UL1TR000124, the Barbra Streisand Women's Cardiovascular Research and Education Program, and the Erika J. Glazer Women's Heart Research Initiative, Cedars-Sinai Medical Center, Los Angeles (CNBM). |
|
| Conflicts of Interest: CNBM has disclosures from iRhythm. JW has disclosures from Abbott Vascular. The other authors do not have conflict of interest. |
|
| Authorship: All authors had access to the data and a role in writing the manuscript. |
Vol 135 - N° 9
P. 1059-1068 - septembre 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
